A Phase 3 interventional study of rVIII-SingleChain in Congenital Hemophilia A, sponsored by CSL Behring. Completed at 37 sites in 19 countries. Open to male participants aged Up to 11 Years. Per ClinicalTrials.gov, last updated 2017-01-27.
Sponsored by CSL Behring (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hemophilia A by CSL Limited — none open to participants now, none under way, none of them phase 3. Hemophilia A · CSL Limited.
Among the 14 studies in Hemophilia A by CSL Limited, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 8th registered.
844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.
Browse Hemophilia A studies →None of the 14 studies in Hemophilia A by CSL Limited is open now. The open studies under Hemophilia A, anywhere →
Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.
This study: Up to 11 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 4 · Phase 3 8 · Phase 4 1
First in 2001; this study’s year is marked. 2 started in 2014.
This study's enrollment of 84 is above the median of 30 across 499 interventional studies indexed under Hemophilia A.
Median enrollment 62 across the 11 interventional studies, 62 across the 3 observational. Of the 14 that completed or were terminated, 5 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under CSL Behring, one of the names counted as CSL Limited. Under that name alone:
CSL Behring is the lead sponsor of 145 studies on the registry; 17 are open to participants now.
Of its 24 completed or terminated interventional studies of FDA-regulated products, 17 (71%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hemophilia A by CSL Limited, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an international, multicenter, open-label study to assess the efficacy, safety, and pharmacokinetic (PK) profile of rVIII-SingleChain in pediatric patients with severe hemophilia A. A minimum of 25 previously treated subjects ≥ 6 to \< 12 years of age and at least 25 subjects \< 6 years of age who have undergone > 50 exposure days (EDs) with a previous Factor VIII (FVIII) product are planned to be enrolled. Subjects will be assigned to either an on-demand or prophylaxis treatment regimen and will receive rVIII-SingleChain at a dose to be determined by the investigator. Hemostatic efficacy will be assessed by the subject/caregiver and the investigator who will assess overall efficacy by a 4-point scale.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be assigned to either an on-demand or prophylaxis regimen and will receive rVIII-SingleChain as an intravenous (IV) infusion. Subjects assigned to a prophylaxis regimen will be treated with 15 to 50 IU/kg of rVIII-SingleChain every second day or 2 to 3 times per week, or at the investigator's discretion, based on available PK data, the FVIII treatment regimen used before enrollment and/or the subject's bleeding phenotype. The dose for on-demand treatment of a bleeding episode is based on the recommendations of the World Federation of Hemophilia (WFH), with a minimum dose of 15 IU/kg. All subjects were to be treated for a minimum of 50 EDs. For the PK evaluation, the subjects will receive a single IV dose of 50 IU/kg of rVIII-SingleChain on Day 1 at the start of the PK evaluation period.
Biological: rVIII-SingleChain
Also known as: Recombinant Factor VIII single chain, CSL627
Treatment Success
Rate of treatment success where treatment success of a bleeding episode is defined as a rating of "excellent" or "good" based on the investigator's overall clinical assessment of hemostatic efficacy (using a 4-point scale of excellent, good, moderate or poor/no response) on the on-demand and prophylaxis regimens combined. The rate of success was based on the number of treated bleeding events; there were 347 treated bleeding events in the Efficacy Population.
Time frame: Up to 1 year
Annualized Bleeding Rate
The annualized bleeding rate was defined as the number of bleeding episodes requiring treatment divided by the efficacy evaluation period in days, x 365.25, and is presented separately for the on-demand regimen and the prophylaxis regimens.
Time frame: Up to 1 year
Percentage of Bleeding Episodes Requiring 1, 2, 3, or More Than 3 Infusions of rVIII-SingleChain to Achieve Hemostasis.
Time frame: Up to 1 year
Consumption of rVIII-SingleChain - IU/kg Per Subject Per Month
Time frame: Up to 1 year
Consumption of rVIII-SingleChain - IU/kg Per Subject Per Year
Time frame: Up to 1 year
Consumption of rVIII-SingleChain - IU/kg Per Bleeding Event
Time frame: Up to 1 year
Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Month
Time frame: Up to 1 year
Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Year
Time frame: Up to 1 year
Incremental Recovery
Incremental recovery expressed as (IU/dL)/(IU/kg) corrected for subject's predose plasma FVIII activity measured using the chromogenic substrate assay.
Time frame: At 1 hour after the start of infusion
Half-life (t1/2) of rVIII-SingleChain
Half-life (t1/2) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.
Time frame: Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.
Area Under the Concentration Curve (AUC)
AUC to the last sample with quantifiable drug concentration (AUC0-t), baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.
Time frame: Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.
Clearance (Cl) of rVIII-SingleChain
Clearance (Cl) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.
Time frame: Immediately before dosing, and at approximately 1, 5, 10, 24, and 48 hours after dosing.
Number of Subjects With Inhibitor Formation to rVIII-SingleChain
The number of subjects who develop inhibitors to rVIII-SingleChain, defined as a rVIII-SingleChain antibody titer of at least 0.6 Bethesda Units (BU) per mL after receiving study drug.
Time frame: At screening, then after dosing at approximately monthly intervals for 6 months, then every 3 months until reaching 50 EDs, and at the end of study visit (up to approximately 12 months).
This multicenter, multinational study enrolled subjects at 37 participating study centers in Australia, Europe, Georgia, Lebanon, Malaysia, Philippines, Switzerland, Thailand, Turkey, Ukraine, and the United States.
| Milestone | rVIII-SingleChain |
|---|---|
| Started | 84 |
| Completed | 65 |
| Not completed | 19 |
| Withdrew: Physician decision | 1 |
| Withdrew: Planned age group closure - no's reached | 17 |
| Withdrew: Adverse event, non-fatal | 1 |
Rate of treatment success where treatment success of a bleeding episode is defined as a rating of "excellent" or "good" based on the investigator's overall clinical assessment of hemostatic efficacy (using a 4-point scale of excellent, good, moderate or poor/no response) on the on-demand and prophylaxis regimens combined. The rate of success was based on the number of treated bleeding events; there were 347 treated bleeding events in the Efficacy Population.
| Percentage of treated bleeding events | Efficacy Population |
|---|---|
| Treatment Success | 96.3 (91.3 to 98.4) |
The annualized bleeding rate was defined as the number of bleeding episodes requiring treatment divided by the efficacy evaluation period in days, x 365.25, and is presented separately for the on-demand regimen and the prophylaxis regimens.
| Treated bleeding episodes per year | On-demand | Prophylaxis |
|---|---|---|
| Annualized Bleeding Rate | 78.56 (35.12 to 86.62) | 3.69 (0.00 to 7.20) |
| Percentage (%) of bleeding episodes | Efficacy Population |
|---|---|
| Requiring 1 infusion | 85.9 |
| Requiring 2 infusions | 9.8 |
| Requiring 3 infusions | 2.3 |
| Requiring > 3 infusions | 2.0 |
| IU/kg per subject per month | On-demand | Prophylaxis |
|---|---|---|
| Consumption of rVIII-SingleChain - IU/kg Per Subject Per Month | 202 (126 to 231) | 378 (153 to 1394) |
| IU/kg per subject per year | On-demand | Prophylaxis |
|---|---|---|
| Consumption of rVIII-SingleChain - IU/kg Per Subject Per Year | 2429 (1508 to 2771) | 4541 (1839 to 16727) |
| IU/kg per event | On-demand | Prophylaxis |
|---|---|---|
| Consumption of rVIII-SingleChain - IU/kg Per Bleeding Event | 25.9 (21 to 78) | 37.0 (16 to 282) |
| number of infusion per subject per month | On-demand |
|---|---|
| Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Month | 7.58 (5.1 to 7.7) |
| number of infusions per subject per year | On-demand |
|---|---|
| Consumption of rVIII-SingleChain (On-demand Regimen) - Number of Infusions Per Subject Per Year | 90.95 (60.9 to 92.3) |
Incremental recovery expressed as (IU/dL)/(IU/kg) corrected for subject's predose plasma FVIII activity measured using the chromogenic substrate assay.
| (IU/dL)/(IU/kg) | Pharmacokinetic Population |
|---|---|
| Incremental Recovery | 1.63 ± 0.329 |
Half-life (t1/2) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.
| hour | Pharmacokinetic Population |
|---|---|
| Half-life (t1/2) of rVIII-SingleChain | 10.3 ± 2.51 |
AUC to the last sample with quantifiable drug concentration (AUC0-t), baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.
| IU*h/dL | Pharmacokinetic Population |
|---|---|
| Area Under the Concentration Curve (AUC) | 1050 ± 286 |
Clearance (Cl) of rVIII-SingleChain, baseline uncorrected; plasma FVIII activity measured using the chromogenic substrate assay.
| mL/h/kg | Pharmacokinetic Population |
|---|---|
| Clearance (Cl) of rVIII-SingleChain | 4.86 ± 1.43 |
The number of subjects who develop inhibitors to rVIII-SingleChain, defined as a rVIII-SingleChain antibody titer of at least 0.6 Bethesda Units (BU) per mL after receiving study drug.
| participants | rVIII-SingleChain |
|---|---|
| Number of Subjects With Inhibitor Formation to rVIII-SingleChain | 0 |
Collected over For the duration of the study, approximately 1 year, 5 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| rVIII-SingleChain | — | 9/84 (10.7%) | 31/84 (36.9%) |
| Event | rVIII-SingleChain |
|---|---|
| Hand fractureInjury, poisoning and procedural complications | 1/84 |
| LacerationInjury, poisoning and procedural complications | 1/84 |
| Splenic ruptureInjury, poisoning and procedural complications | 1/84 |
| Inhibiting antibodies positiveInvestigations | 1/84 |
| AnaemiaBlood and lymphatic system disorders | 1/84 |
| Device occlusionGeneral disorders | 1/84 |
| Systemic inflammatory response syndromeGeneral disorders | 1/84 |
| DyspepsiaGastrointestinal disorders | 1/84 |
| BacteraemiaInfections and infestations | 1/84 |
| PneumoniaInfections and infestations | 1/84 |
| Event | rVIII-SingleChain |
|---|---|
| NasopharyngitisInfections and infestations | 14/84 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/84 |
| CoughRespiratory, thoracic and mediastinal disorders | 7/84 |
| HeadacheNervous system disorders | 7/84 |
| Head injuryInjury, poisoning and procedural complications | 5/84 |
| PyrexiaGeneral disorders | 5/84 |
| Age, Categorical(Participants) | rVIII-SingleChain |
|---|---|
| <=18 years | 84 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Age, Continuous(years) | rVIII-SingleChain |
|---|---|
| Mean | 6.6 ± 3.11 |
| Gender(Participants) | rVIII-SingleChain |
|---|---|
| Female | 0 |
| Male | 84 |
| Type of FVIII product used before enrollment(participants) | rVIII-SingleChain |
|---|---|
| Plasma product | 33 |
| Recombinant Product | 49 |
| Unknown | 2 |
| Treatment modality of FVIII therapy before enrollment(participants) | rVIII-SingleChain |
|---|---|
| Prophylaxis | 60 |
| On-Demand | 24 |
The record gives a start of Mar 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lonoctocog alfa